Efforts to keep pace with antimicrobial resistance and improve detection moved forward on several fronts. A new study reported a rapid fluorescence PCR approach to spot macrolide-resistant Mycoplasma pneumoniae in hours—aiming to reduce treatment delays and limit unnecessary antibiotic use when resistance is present. In prevention and infection control, research on OM-89 (Uro-Vaxom) suggested a second mechanism beyond immune stimulation: bladder epithelial lysosomal activation that helps clear intracellular E. coli, potentially addressing recurrent UTI biology that antibiotics alone cannot fully solve. On the resistance surveillance side, a study in Jordan’s ICU surveillance data found more than one in three Gram-negative infections resistant to carbapenems—highlighting where stewardship and new interventions must target hardest-hit units. Together, the work signals a multi-pronged response: faster resistance-aware diagnostics, deeper mechanistic understanding for recurrence prevention, and more granular surveillance to guide where new therapies are most needed.